/MEDP
Medpace Holdings, Inc.
MEDP • NASDAQMEDP • NASDAQ • Healthcare
$454.96-0.04%-0.19
$454.96-0.04%(-0.19)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
93Bullish
Risk
62Low Risk
Momentum
26Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
30.1%▼1.1pp
Revenue after COGS
Operating
21.1%▼0.0pp
After operating expenses
Net
17.8%▼1.3pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
35.9
Price vs earnings
EV/EBITDA
28.0
Enterprise value
FCF Yield
4.2%
Cash generation
Earnings Yield
2.8%
Inverse of P/E
Capital Efficiency
68
GoAI Quality ScoreExcellent
★Elite Efficiency – Buyback Driven
Very high ROE-ROA gap driven by shareholder-friendly capital allocation (buybacks), not excessive debt. Interest coverage is elite.
ROEReturn on Equity
98.3%Strong
ROAReturn on Assets
22.8%Strong
ROICReturn on Invested Capital
67.9%Strong
Financial Health
Current RatioWeak
0.74
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-0.43x
Debt repayment capacity (<3x)
Income QualityStrong
1.58
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.53B | $2.11B | $1.89B | $1.46B | $1.14B |
| Gross Profit | $760.62M | $656.30M | $524.50M | $432.44M | $328.15M |
| Gross Margin | 30.1% | 31.1% | 27.8% | 29.6% | 28.7% |
| Operating Income | $534.93M | $446.87M | $336.82M | $278.70M | $198.62M |
| Net Income | $451.12M | $404.39M | $282.81M | $245.37M | $181.85M |
| Net Margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% |
| EPS | $15.64 | $13.06 | $9.20 | $7.57 | $5.06 |
Average Price Target
$534.17▲ 17.4% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Medpace Holdings, Inc., the average price target is $534.17, with a high forecast of $582.00 and a low forecast of $460.00. The average price target represents a 17.4% increase from the current price of $454.96.
Highest
$582.00
Average
$534.17
Lowest
$460.00
Rating Distribution
Strong Buy
0
0%
Buy
4
24%
Hold
12
71%
Sell
1
6%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays▲ Upgrade
Underweight→Equal Weight
2026-03-06TD Cowen▲ Upgrade
Sell→Hold
2026-02-18Jefferies▲ Upgrade
Hold→Buy
2026-02-13Leerink Partners● Maintain
Market Perform
2026-02-11Truist Securities● Maintain
Hold
2026-02-11Barclays● Maintain
Underweight
2026-02-11Barclays● Maintain
Underweight
2025-12-15Truist Securities● Maintain
Hold
2025-10-27TD Cowen● Maintain
Sell
2025-10-24Mizuho● Maintain
Outperform
2025-10-24Earnings History & Surprises
BEAT RATE
100%
Last 18 quarters
AVG SURPRISE
+16.2%
EPS vs Estimate
BEATS / MISSES
18/0
Last 18 quarters
LATEST EPS
$4.67
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+11.7%
$4.67 vs $4.18
Q4 '25
+9.3%
$3.86 vs $3.53
Q3 '25
+4.0%
$3.10 vs $2.98
Q2 '25
+19.9%
$3.67 vs $3.06
Q1 '25
+24.0%
$3.67 vs $2.96
Q4 '24
+8.3%
$3.01 vs $2.78
Q3 '24
+8.3%
$2.75 vs $2.54
Q2 '24
+29.6%
$3.20 vs $2.47
Q1 '24
+10.8%
$2.46 vs $2.22
Q4 '23
+8.3%
$2.22 vs $2.05
Q3 '23
+1.0%
$1.93 vs $1.91
Q2 '23
+26.1%
$2.27 vs $1.80
No investor questions available.
Latest News
No news available